Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05352828 · ClinicalTrials.gov registry record · Phase 1
Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy
A Phase 1 study of Classical Hodgkin Lymphoma and Hodgkin Disease Recurrent, sponsored by Tessa Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 5
- Study locations
NCT05352828 is a Phase 1 study of Classical Hodgkin Lymphoma and Hodgkin Disease Recurrent that is active but no longer recruiting, run by Tessa Therapeutics. The registered enrollment target is 15 participants, below the 78-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (81% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05352828, a Phase 1 study of Classical Hodgkin Lymphoma and Hodgkin Disease Recurrent, is active but no longer recruiting, sponsored by Tessa Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard frontline therapy.
Conditions Studied
Interventions
- DRUG Fludarabine
- DRUG Nivolumab
- DRUG Bendamustine
- DRUG Autologous CD30.CAR-T
Study Locations (5)
Texas
- Baylor College of Medicine - Houston
- MD Anderson Cancer Center - Houston
California
- City of Hope National Medical Center - Duarte
Florida
- University of Miami - Miami
North Carolina
- UNC Lineberger Comprehensive Cancer Center - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-07-25 |
| Est. Completion | 2037-12-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05352828
The ClinicalTrials.gov registry entry for NCT05352828 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 8 other Classical Hodgkin Lymphoma trials with a reported enrollment target (81% lower). The listed sponsor is Tessa Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Classical Hodgkin Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Fludarabine is the first listed.
NCT05352828 reports 5 study locations spanning 4 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT05352828 about?
NCT05352828 is a clinical study titled "Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy". This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Ho...
What is the current status of trial NCT05352828?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2022-07-25. Estimated completion is 2037-12-15.
What conditions does trial NCT05352828 study?
This clinical trial studies the following conditions: Classical Hodgkin Lymphoma, Hodgkin Disease Recurrent, Hodgkin Disease Refractory.
What interventions are being tested in trial NCT05352828?
The interventions under investigation include: Fludarabine (DRUG), Nivolumab (DRUG), Bendamustine (DRUG), Autologous CD30.CAR-T (DRUG).
Who is sponsoring clinical trial NCT05352828?
This trial is sponsored by Tessa Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05352828 being conducted?
This trial has 5 study locations across California, Florida, North Carolina, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Classical Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
RECRUITING · Phase 1
-
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
RECRUITING · Phase 1
-
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Itacitinib + Everolimus in Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
-
Phase Ib of L-NMMA and Pembrolizumab
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.